Mechanical Ventilation and Death During Pregnancy Complicated by COVID-19: A Prognostic Analysis from the Brazilian COVID-19 Registry Score

Zilma Silveira Nogueira Reis
Universidade Federal de Minas Gerais Faculdade de Medicina

Regina Amélia Lopes Pessoa de Aguiar
Universidade Federal de Minas Gerais Faculdade de Medicina

Thaís Lorenna Souza Sales
Universidade Federal de São João del-Rei: Universidade Federal de Sao Joao del-Rei

Amanda de Oliveira Maurílio
Hospital São João de Deus: Hospital Sao Joao de Deus

Ana Luiza Bahia Alves Scotton
Hospital Regional Antônio Dias

Bárbara Lopes Farace
Universidade Federal de Minas Gerais Hospital Risoleta Tolentino Neves

Carolina Marques Ramos
Hospital Júlia Kubitschek: Hospital Julia Kubitschek

Christiane Corrêa Rodrigues Cimini
Universidade Federal dos Vales do Jequitinhonha e Mucuri

Clareci Silva Cardoso
Universidade Federal de São João del-Rei: Universidade Federal de Sao Joao del-Rei

Claudete Rempel
Hospital Bruno Bom

Daniela Ponce
Hospital das Clinicas da Faculdade de Medicina de Botucatu

Edilson Cezar
Hospital Universitário Canoas

Emanuele Marianne Souza Kroger
Hospital Júlia Kubitschek: Hospital Julia Kubitschek

Euler Roberto Fernandes Manenti
Hospital Universitário Canoas

Felipe Ferraz Martins Graça Aranha
Hospital SOS Cardio

Fernando Anschau
Hospital Nossa Senhora da Conceição: Hospital Conceicao
Gabriela Petry Crestani
Hospital Mãe de Deus: Hospital Mae de Deus

Gisele Alsina Nader Bastos
Hospital Moinhos de Vento

Joice Coutinho de Alvarenga
Hospital João XXIII: Hospital Joao XXIII

Juliana Machado-Rugolo
Hospital das Clinicas da Faculdade de Medicina de Botucatu

Karen Brasil Ruschel
Hospital Mãe de Deus: Hospital Mae de Deus

Liege Barella Zandoná
Hospital Bruno Born

Lílian Santos Pinheiro
Universidade Federal dos Vales do Jequitinhonha e Mucuri

Luana Yasmin Bochard Chiaravalle
Hospital SOS Cardio

Luiza Elem Almeida Santos
Hospital Regional Antônio Dias

Maiara Anschau Floriani
Hospital Moinhos de Vento

Matheus Fernandes Lopes Martins
Hospital Márcio Cunha: Hospital Marcio Cunha

Milton Henriques Guimarães Júnior
Hospital Márcio Cunha: Hospital Marcio Cunha

Petrônio José de Lima Martelli
Universidade Federal de Pernambuco

Rafaela dos Santos Charão de Almeida
Hospital Nossa Senhora da Conceição: Hospital Nossa Senhora da Conceicao

Raphael Castro Martins
Hospital Tacchini

Roberta Pozza
Hospital Tacchini

Rodolfo Lucas Silva Mourato
Universidade Federal de São João del-Rei: Universidade Federal de Sao Joao del-Rei

Andresa Fontoura Garbini
Hospital Nossa Senhora da Conceição: Hospital Nossa Senhora da Conceicao

Magda Carvalho Pires
Universidade Federal de Minas Gerais

Milena Soriano Marcolino (✉ milenamarc@gmail.com )
Universidade Federal de Minas Gerais Faculdade de Medicina  https://orcid.org/0000-0003-4278-3771
Abstract

Background

Assessing predictors of critical outcomes in COVID-19 may advise timely treatments and better prepare facilities to overcome extra adversities during pregnancy. However, many clinical parameters of existent scores are deeply modified by physiologic adaptations. Our aim was to assess the feasibility of a prognosis score developed for general hospitalized adults with COVID-19 in Brazil to predict clinical adverse outcomes in pregnant women upon hospital admission.

Methods

This is a multicenter retrospective substudy of the Brazilian COVID-19 Registry, a multicenter cohort analysis in Brazilian hospitals, which provided an accurate score to predict in-hospital death. The present analysis assessed the performance of this model, ABC$_2$-SPH, based on data of 3978 patients, to assess poor clinical outcomes in data from 85 pregnant women admitted due to COVID-19 from March 1, 2020, to May 5, 2021, in 19 Brazilian hospitals. The primary outcomes were death and the composite mechanical ventilation or death, and secondary were pregnancy outcomes and severe/critical Covid-19. The overall discrimination of the model was presented as the area under the receiver operating characteristic curve (AUROC).

Results

Thirty-one (36.5%) pregnant women had critical or severe COVID-19. Most of them had no previous comorbidities (64.7%). The median gestational age was 31.0 (26.0, 36.2) weeks; 38 (44.7%) women gave birth during hospitalization by Covid-19, most of them by C-section (76.3%). The need for mechanical ventilation or death occurred in 14 (17.3%) pregnant women. Severe and critical COVID-19 in pregnant women was associated with diabetes, inflammatory markers, and abnormal vital signals observed at admission. The model was not able to identify adverse clinical outcomes. The AUROC of predicting severe/critical Covid-19 illness was 0.595 (95% CI: 0.424-0.754); AUROC of the inpatient death discrimination was 0.683 (95% CI: 0.293-0.945), as the AUROC of mechanical ventilation or death discrimination was 0.591 (95% CI: 0.434-0.75).

Conclusions

The model ABC$_2$-SPH developed in Brazilian general patients was not able to identify adverse clinical outcomes in pregnant women with COVID-19. We warn against the use of general inpatients COVID-19 prognosis in pregnant women. A more useful model for clinical prognosis is necessary concerning the specificities of pregnancy affected by COVID-19.

Background
Coronavirus disease 19 (COVID-19) has quickly spread worldwide with higher morbidity and lethality than other coronaviruses (1), threatening people's lives, mainly those more vulnerable or under adverse social contexts (2, 3). Recent data raised concern about the impact of COVID-19 on pregnancy, since the pandemic severely hit more vulnerable countries with big birth rates (4-6). The impact of SARS-CoV-2 infection on pregnancy became more evident in controlled studies, revealing consistent increase in severe maternal morbidity and mortality and neonatal complications when comparing pregnant women with and without COVID-19 diagnosis (5). Pregnant women with comorbidities, such as diabetes, hypertensive diseases, heart disease and lung diseases deserve special attention, as they seem to be susceptible to the severe and critical forms of COVID-19, with higher risk of adverse outcomes (7).

Even though the majority of pregnant women are healthy and younger than most COVID-19 patients (8), during pregnancy there are significant anatomical and physiological changes that affect every organ system in the body (9). It is believed that such changes may interfere with the progression of COVID-19 (9, 10).

The assessment of clinical characteristics and outcomes in pregnant women who are hospitalized with COVID-19, as well as the factors potentially associated with adverse maternal outcomes in those patients, is of utmost importance for public health. It may help health managers and stakeholders to better prepare facilities to overcome extra-adversities during the pregnancy-puerperal period (8). However, rapid scoring systems for prognosis applicable during pregnancy are challenging. There are specificities in clinical parameters in pregnant women, so scores developed for non-pregnant cannot be applied in pregnant women without previous assessment. In this context, there is a lack of studies of risk or prognosis score for COVID-19 in pregnant women.

Therefore, the primary aim of this pilot study is to assess the ability of a COVID-19 prognosis score, developed for general hospitalized adults with COVID-19 in Brazil, to predict mechanical ventilation and death in pregnant women upon hospital admission. Additionally, to assess the occurrence of pregnancy adverse outcomes, as well as severe and critical COVID-19.

**Methods**

This is a multicenter retrospective substudy of the Brazilian COVID-19 Registry, a multicenter cohort study of consecutive patients with laboratory-confirmed COVID-19 hospitalized between March and September 2020, in 37 Brazilian public and private hospitals, as previously described (11, 12). It adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline (13).

Study data were collected and managed by trained health professionals using Research Electronic Data Capture (REDCap) hosted at the Telehealth Center of the University Hospital, *Universidade Federal de Minas Gerais* (14, 15). Over three hundred variables were collected from medical records, involving clinical, laboratory and imaging characteristics at admission, as well as in-hospital outcomes related to COVID-19. Obstetric data were gestational age, pregnancy complications at admission, whether there was delivery and, if so, mode of delivery, birth weight and vital state of the newborn. The study protocol and a coding manual guiding data collection with details and the definition of each variable was agreed with the network of researchers (11).
This Registry study previously established a prognostic scoring model for in-hospital mortality for COVID-19 patients, based on comorbidities, clinical characteristics, laboratory and imaging findings at hospital presentation, the ABC$_2$-SPH score (12). The score has shown high discriminatory value (AUROC 0.844, 95% CI 0.829 to 0.859), which was confirmed in the Brazilian (0.859 [95% CI 0.833 to 0.885]) and Spanish (0.894 [95% CI 0.870 to 0.919]) validation cohorts, and displayed better discrimination ability than other existing scores (12).

For the score development and validation, patients who developed the first COVID-19 symptoms during admission due to other conditions and those who were admitted in another hospital first (not part of the cohort) were excluded, as the score was intended to be applicable upon hospital presentation. For the present analysis, the external validation group gathered data of pregnant women who were admitted from March 1, 2020, to May 5, 2021. We kept the first exclusion criteria, but opted to maintain women who were transferred between hospitals, as in Brazil only certain hospitals were selected to treat pregnant women with COVID-19 in the public health system, so if a pregnant women seek care in a non-reference center, she was transferred to a reference center and it would not be adequate to exclude those patients. After exclusion criteria, 85 pregnant women were identified in 19 of 37 multicentric network centers (Figure 1), in 12 different cities from 5 Brazilian states. Eight of them were public, 13 were teaching hospitals and 12 were reference centers for COVID-19 treatment, gathering average 322,8 beds (ranging from 60 to 784 beds).

**Figure 1** Flowchart of COVID-19 pregnant women included in the study

Clinical characteristics, laboratory data and obstetric characteristics at admission, as well as events that occurred during hospital stay were collected for the present analysis.

**Outcomes**

The primary outcomes were death, and the composite outcome of mechanical ventilation or death. The secondary outcomes included pregnancy outcomes and the occurrence of severe and critical COVID-19, according to World Health Organization criteria (16). Pregnancy outcomes included preterm birth, c-section, preeclampsia, maternal death, and immediate neonatal vital state. Occurrence of severe and critical COVID-19 considered at least one of following conditions (16):

- Acute respiratory distress syndrome (ARDS), based on chest imaging and oxygenation impairment demanding mechanical ventilation.
- Sepsis, based on signs of organ dysfunction, including abnormal mental status, difficult or fast breathing, low oxygen saturation, renal failure, cardiac failure, laboratory evidence of coagulopathy, thrombocytopenia, acidosis, high lactate, or hyperbilirubinemia.
- Shock, based on persistent hypotension despite volume resuscitation, requiring vasopressors to maintain mean arterial pressure (MAP) $\geq$ 65 mmHg and serum lactate level > 2 mmol/L.
- Sequential Organ Failure Assessment (SOFA) score > 2.
- Cardiac arrest, resuscitation or death.
• Severe pneumonia demanding ventilatory support, peripheral oxygen saturation (SpO$_2$) <90% on room air, respiratory frequency >30ipm had classification as severe COVID-19.

**Statistical analysis**

ABC$_2$-SPH development and validation methods followed guidance from the Transparent Reporting of a Multivariable Prediction Model for Individual Prediction or Diagnosis (TRIPOD) checklist and Prediction Model Risk of Bias Assessment Tool (PROBAST), and are described elsewhere (12, 17, 18). In brief, generalized additive models (GAM) were used to examine the relationships between in-hospital mortality and potential predictors, selected based on clinical reasoning and literature review. Least absolute shrinkage and selection operator (LASSO) logistic regression was used to derive the mortality score, which was external validated (12).

Descriptive analysis of the pregnant women's clinical characteristics stratified by COVID-19 severity and the cohort of (non-pregnant) patients was performed, concerning the frequency, variability, and central tendency measures. Continuous variables were summarized using medians and interquartile ranges (IQR), whereas counts and percentages were used for categorical variables. For comparisons, the Chi-squared test or Fisher test was used for the independence hypothesis, and the Mann–Whitney test compared the numerical variables between the groups. A p-value less than 0.05 was considered statistically significant.

Calibration of the model applied to pregnant women was assessed graphically by plotting the predicted outcome of interest (death, composite outcome, or severe/critical disease) probabilities against the observed outcome, testing intercept equals zero and slope equals one. The area under the receiver operating characteristic curve (AUROC) described model's discrimination. Confidence intervals (95% CI) for AUROC were obtained through 2000 bootstrap samples.

Statistical analysis was performed with R software (version 4.0.2) with the tidyverse, pROC, rms packages.

**Results**

Clinical characteristics and laboratory findings of the 85 pregnant women upon hospital presentation are shown in Table 1. Their comparison to the ones who were excluded is shown in Table S3.
Table 1
Demographic and clinical characteristics at admission of the pregnant women included in the validation analysis

| Characteristic                  | Overall       | Critical / Severe | Non Critical / Severe | P-value² |
|--------------------------------|---------------|-------------------|-----------------------|----------|
|                                | N = 85¹       | Non missing cases | N = 31¹               | Non missing cases |         |
| Age (years)                    | 30.0 (26.0, 37.0) | 85 (100%)        | 30.0 (27.0, 38.0)    | 31 (100%) | 30.0 (26.0, 35.0) | 54 (100%) | 0.418 |
| Comorbidities                  |               |                   |                       |           |                       |           |      |
| Hypertension                   | 8 (9.4%)      | 85 (100%)        | 2 (6.5%)              | 31 (100%) | 6 (11.1%)              | 54 (100%) | 0.705 |
| Diabetes mellitus              | 16 (18.8%)    | 85 (100%)        | 10 (32.3%)            | 31 (100%) | 6 (11.1%)              | 54 (100%) | 0.035 |
| Obesity (BMI ≥ 30kg/m²)        | 15 (17.6%)    | 85 (100%)        | 9 (29.0%)             | 31 (100%) | 6 (11.1%)              | 54 (100%) | 0.073 |
| Symptoms*                      |               |                   |                       |           |                       |           |      |
| Adynamic                       | 8 (9.4%)      | 85 (100%)        | 3 (9.7%)              | 31 (100%) | 5 (9.3%)               | 54 (100%) | >0.999 |
| Ageusia                        | 12 (14.1%)    | 85 (100%)        | 2 (6.5%)              | 31 (100%) | 10 (18.5%)             | 54 (100%) | 0.196 |
| Anosmia                        | 17 (20.0%)    | 85 (100%)        | 2 (6.5%)              | 31 (100%) | 15 (27.8%)             | 54 (100%) | 0.037 |
| Headache                       | 25 (29.4%)    | 85 (100%)        | 9 (29.0%)             | 31 (100%) | 16 (29.6%)             | 54 (100%) | >0.999 |
| Rhinorrhea                     | 19 (22.4%)    | 85 (100%)        | 5 (16.1%)             | 31 (100%) | 14 (25.9%)             | 54 (100%) | 0.439 |
| Dyspnea                        | 52 (61.2%)    | 85 (100%)        | 23 (74.2%)            | 31 (100%) | 29 (53.7%)             | 54 (100%) | 0.102 |
| Sore throat                    | 12 (14.1%)    | 85 (100%)        | 3 (9.7%)              | 31 (100%) | 9 (16.7%)              | 54 (100%) | 0.522 |

¹Statistics presented: Median (IQR); n (%)

²Statistical tests performed: Wilcoxon rank-sum test; Fisher’s exact test; chi-square test of independence

BMI: body mass index; COPD: chronic obstructive pulmonary disease; HCO₃⁻: bicarbonate; NL ratio: neutrophils-to-lymphocytes ratio; pH: hydrogen potential;

pCO₂: carbon dioxide partial pressure; pO₂: oxygen partial pressure; SF ratio: SpO₂/FiO₂ ratio.

* There was no patient with neurological symptoms, arthralgia or skin rash
| Characteristic                  | Overall N = 85 | Non Critical / Severe N = 54 | P-value² |
|--------------------------------|----------------|-----------------------------|----------|
|                                | Non missing cases | Non missing cases |          |
| Fever                          | 41 (48.2%)     | 19 (61.3%)                 | 0.110    |
| Myalgia                        | 24 (28.2%)     | 5 (16.1%)                  | 0.103    |
| Nausea/vomiting                | 13 (15.3%)     | 4 (12.9%)                  | 0.761    |
| Productive cough               | 5 (5.9%)       | 4 (12.9%)                  | 0.057    |

**Clinical presentation upon hospital admission**

| Characteristic                  | Overall | Non Critical / Severe | P-value² |
|--------------------------------|---------|-----------------------|----------|
|                                | N = 85  | N = 54                |          |
|                                | (100.0%)| (100.0%)              |          |
| Glasgow coma score = 15        | 85      | 31                    |          |
| Respiratory rate (irpm)        | 22.0 (19.0, 25.0) | 25.0 (22.0, 26.5) | 0.003    |
| SF ratio                       | 457.1 (442.9, 466.7) | 440.5 (341.7, 461.9) | 0.003    |
| Heart rate (bpm)               | 100.0 (92.0, 112.0) | 110.0 (98.0, 123.5) | 0.009    |
| Systolic blood pressure ≥ 90 (mm Hg) | 84 (99%) | 31 (100%) | 0.016    |
| Inotrope requirement           | 2 (2.4%) | 2 (6.5%)              |          |
| Diastolic blood pressure ≤ 60 (mm Hg) | 84 (99%) | 31 (100%) | 0.166    |

1 Statistics presented: Median (IQR); n (%)

2 Statistical tests performed: Wilcoxon rank-sum test; Fisher’s exact test; chi-square test of independence

BMI: body mass index; COPD: chronic obstructive pulmonary disease; HCO3−: bicarbonate; NL ratio: neutrophils-to-lymphocytes ratio; pH: hydrogen potential;

pCO₂: carbon dioxide partial pressure; pO₂: oxygen partial pressure; SF ratio: SpO₂/FiO₂ ratio.

* There was no patient with neurological symptoms, arthralgia or skin rash.
| Characteristic                | Overall N = 85 | Critical / Severe N = 31 | Non Critical / Severe N = 54 | P-value² |
|------------------------------|----------------|--------------------------|-------------------------------|---------|
| Inotrope requirement         | 2 (2.4%)       | 2 (6.5%)                 |                               |         |
| Laboratory exams             |                |                          |                               |         |
| Hemoglobin (g/L)             | 11.8 (10.8, 12.5) | 11.4 (10.6, 12.1) | 11.9 (11.0, 12.6) | 0.144   |
| Platelet count (109/L)       | 201,000.0 (167,000.0, 243,000.0) | 183,500.0 (159,000.0, 213,250.0) | 217,000.0 (176,500.0, 252,500.0) | 0.064   |
| NL ratio                     | 4.9 (3.4, 7.1) | 6.7 (5.1, 8.5)          | 3.7 (2.7, 5.9)                | <0.001  |
| Lactate value                | 1.1 (0.8, 1.5) | 1.0 (0.7, 1.3)          | 1.2 (0.9, 1.6)                | 0.308   |
| C reactive protein (mg/L)    | 47.0 (19.0, 100.0) | 90.4 (37.0, 162.6) | 33.1 (12.5, 64.1)          | 0.001   |
| Urea (mg/dL)                 | 15.0 (11.2, 19.5) | 12.0 (9.9, 18.0) | 15.0 (13.0, 20.0)          | 0.029   |

¹Statistics presented: Median (IQR); n (%)

²Statistical tests performed: Wilcoxon rank-sum test; Fisher’s exact test; chi-square test of independence

BMI: body mass index; COPD: chronic obstructive pulmonary disease; HCO₃⁻: bicarbonate; NL ratio: neutrophils-to-lymphocytes ratio; pH: hydrogen potential;

pCO₂: carbon dioxide partial pressure; pO₂: oxygen partial pressure; SF ratio: SpO₂/FiO₂ ratio.

* There was no patient with neurological symptoms, arthralgia or skin rash
| Characteristic       | Overall | Critical / Severe | Non Critical / Severe | P-value² |
|---------------------|---------|-------------------|-----------------------|----------|
|                     | N = 85¹ | N = 31¹           | N = 54¹               |          |
| Creatinine (mg/dL)  | 0.6 (0.5, 0.7) | 0.6 (0.5, 0.7) | 0.6 (0.5, 0.7) | 0.982    |
|                     | 72 (85%) | 28 (90%)         | 44 (81%)             |          |
| HCO3-               | 18.8 (17.2, 20.0) | 18.0 (17.0, 20.0) | 18.9 (18.0, 20.0) | 0.752    |
|                     | 42 (49%) | 22 (71%)         | 20 (37%)             |          |
| pH                  | 7.4 (7.4, 7.5) | 7.4 (7.4, 7.5) | 7.4 (7.4, 7.5) | 0.105    |
|                     | 43 (51%) | 22 (71%)         | 21 (39%)             |          |
| Arterial pO₂        | 85.3 (72.3, 105.6) | 84.7 (73.5, 103.0) | 87.6 (67.0, 104.2) | 0.903    |
|                     | 43 (51%) | 22 (71%)         | 21 (39%)             |          |
| Arterial pCO₂       | 29.0 (26.2, 30.9) | 30.0 (25.2, 33.4) | 29.0 (27.0, 30.0) | 0.395    |
|                     | 43 (51%) | 22 (71%)         | 21 (39%)             |          |

¹Statistics presented: Median (IQR); n (%)

²Statistical tests performed: Wilcoxon rank-sum test; Fisher’s exact test; chi-square test of independence

*BMI: body mass index; COPD: chronic obstructive pulmonary disease; HCO3-: bicarbonate; NL ratio: neutrophils-to-lymphocytes ratio; pH: hydrogen potential; pCO₂: carbon dioxide partial pressure; pO₂: oxygen partial pressure; SF ratio: SpO₂/FiO₂ ratio.

*There was no patient with neurological symptoms, arthralgia or skin rash.

Table 1 Characteristics of the pregnant women included in the validation analysis, according to COVID-19 severity

The majority of the included pregnant women had no previous comorbidities (64.7%). Diabetes mellitus (18.8%), obesity (17.6%), and chronic hypertension (9.4%) were the most frequent diseases. Thirty one (36.5%) developed critical or severe COVID-19. Hypertensive disorders compromised 16 (18.8%) patients, with no difference between groups of COVID-19 severity (p=0.702). Diabetes was more frequent in the severe/critical COVID-19 women (32.3% vs. 11.1%, p=0.035).

Dyspnea (61.2%), headache (29.4%) and myalgia (28.2%) were the most frequent symptoms, and the frequency of symptoms was similar between the groups of severity, except for anosmia, more frequent in the non-severe/critical group (27.8%) when compared with the severe/critical one (6.5%). With regards to clinical presentation upon hospital admission, patients who developed severe/critical disease also had significantly lower median SpO₂/FiO₂ ratio, higher median respiratory and heart rates, higher median neutrophils-to-lymphocytes ratio and C-reactive protein, and slightly lower median urea values than the ones who did not developed severe disease (Table 1).

Concerning obstetric characteristics (Table 2), the median gestational age was 31.0 (26.0, 36.2) weeks overall, and there was no difference with regards to COVID-19 severity (31.0 [27.5-34.0] vs. 32.0 [26.0-38.0],
Thirty-eight (44.7%) women gave birth, most of them by C-section (76.3%), with a non-significant difference between groups (87.5% in severe/critical group vs. 68.2% in non-severe one, p=0.254). One woman delivered twins, totaling 39 newborns, 38 (97.4%) of them alive at hospital discharge. Birth weight, five-minute Apgar score, and being born alive were similar between groups.

Table 2
Characteristics of the newborns of women with birth during COVID-19 hospital stay

| Label                      | Overall | Critical / Severe | Non Critical / Severe | P-value² |
|----------------------------|---------|-------------------|-----------------------|----------|
| Characteristic             | N =85 women / 39 newborns | N = 31 | Non missing cases | N = 55 | Non missing cases |
| Gestational age (weeks)    | 31.0 (26.0, 36.2) | 31.0 (27.5, 34.0) | 32.0 (26.0, 38.0) | 0.472 |
| Gestational hypertensive disorder | 16 (18.8%) | 7 (22.6%) | 9 (16.7%) | 0.702 |
| Gestational complication   | 32 (39.0%) | 16 (51.6%) | 16 (31.4%) | 0.112 |
| Vaginal birth or C-Section | 38 (45%) | 16 (52%) | 22 (41%) | 0.254 |
| Cesarean                   | 29 (76.3%) | 14 (87.5%) | 15 (68.2%) |         |
| Natural birth              | 9 (23.7%) | 2 (12.5%) | 7 (31.8%) |         |
| Childbirth                 | 37 (45.1%) | 16 (51.6%) | 21 (41.2%) | 0.489 |
| Born alive                 | 38 (97.4%) | 16 (100.0%) | 22 (95.7%) | >0.999 |
| Birth weight               | 3,040.0 (2,430.0, 3,365.0) | 2,622.5 (2,086.2, 3,392.0) | 3,050.0 (2,725.0, 3,290.0) | 0.689 |
| Apgar Score                | 8.0 (7.0, 9.0) | 8.0 (6.2, 8.8) | 8.0 (7.8, 9.0) | 0.410 |

¹Statistics presented: n (%); Median (IQR)

²Statistical tests performed: Fisher's exact test; Wilcoxon rank-sum test

Table 2 Characteristics of pregnancy at admission and newborns of women with birth during COVID-19 hospital stay

The comparison between the pregnant women included in the pilot validation and the ABC₂-SPH model-derivation cohort is shown in Table S1, and Table S2. Pregnant women were markedly younger than the
group of patients who derived the model of prediction (30 [26–37] vs. 60 [48-72] years-old, p<0.001), and they had a lower frequency of comorbidities. Coronary artery disease, heart failure, atrial fibrillation/flutter, stroke, and chronic obstructive pulmonary disease (COPD) were not observed among the pregnant group. There were significant differences comparing laboratory findings and vital signals between groups, such as lower hemoglobin levels (11.8 [10.8-12.5] vs. 13.3 [12.1-14.5], p<0.001), higher heart rate (median 100 [92-112] vs. 88[78-100] bpm, p<0.001), and higher SpO₂/FiO₂ ratio (457.1 [442.9-366.7] vs. 428 [332.1-452.4], p<0.001) in pregnant women.

With regards to patient outcomes (Table 2), in-hospital mortality was 20.4% and 3.5% for the model-derivation cohort compared to the pregnant women (p<0.001). Hospital and intensive care unit length of stay were also longer in the general group of patients than pregnant women (p=0.010 and p=0.048, respectively).

Fourteen pregnant women needed mechanical ventilation (17.3%), and 3 (3.5%) died in hospital. All of the dead women needed mechanical ventilation. The ABC₂-SPH model was not able to identify high-risk pregnant women (Figure 2). Discrimination was poor for inhospital mortality (area under the ROC curve [AUROC] 0.683 [95% CI: 0.293-0.945]), the composite mechanical ventilation or death (AUROC 0.591 [95% CI: 0.434-0.75]), and for predicting severe or critical COVID-19 (AUROC 0.595 [95% CI: 0.424-0.754]) (Figure 3).

**Figure 2** Discrimination of ABC₂-SPH Score in the sample of pregnant women (n=85) to predict death (A), death or mechanical ventilation (B) or critical disease (C)

**Figure 3** The observed and expected death (A), composite of mechanical ventilation or death (B) and severe/critical COVID-19 (C), for each quartile of pregnant women risk

**Discussion**

The main contribution of present analysis was testing the ABC₂-SPH model developed from a cohort of 3978 patients (12), based on clinical and laboratory characteristics upon hospital presentation, in an external validation with 85 pregnant women from 19 Brazilian hospitals. Even though the ABC₂-SPH model presented very high discrimination in external validation in cohorts of general hospitals (12), this model failed to discriminate the adverse clinical results in pregnant women. Calibration curves showed that the ABC₂-SPH model overestimated the risk of death, or the composite of mechanical ventilation or death in pregnant women. Additionally, the risk of severe/critical progression of COVID-19 was underestimated in cases of low probability and overestimated in cases of higher probability of the outcome (Figure 2).

Our interpretation is that the set of prognosis markers of COVID-19 in pregnancy are not the same as the ones for the non-pregnant population admitted with the disease. This finding itself could contribute to an understanding of the poor outcomes as COVID-19 maternal mortality. According to Brazilian data, pregnancy complicated by COVID-19 is a serious burden for the hospital maternity services. Pregnant women accounted for 0.8/1000 of 20,350,142 confirmed cases in the country until Aug/2021 (19, 20). However, the rate of mortality was 10.5%, 3.8 times higher than the rate of 2.8% of the national mortality (19).
Across the studies in non-pregnant populations, male sex, increasing age and underlying illness, such as cardiovascular diseases and diabetes, increased the risk of poor outcomes (21, 22). The ABC₂-SPH predictive model was developed upon a set of covariates upon hospital presentation to predict death: age, chronic diseases (hypertension, diabetes mellitus, obesity, coronary artery disease, heart failure, atrial fibrillation or flutter, cirrhosis, cancer, chronic obstructive pulmonary disease and previous stroke), heart rate and \( \text{SpO}_2/\text{FiO}_2 \) ratio, allied to low platelets, C-reactive protein and urea (12). Such predictors might score differently in pregnant women, since they are deeply modified by physiologic adaptations, such as the increase in heart rate, which itself may overestimate the risk estimated by the score in at least 5%, and maternal response to infections. Our analysis reveals how distinct these groups are in terms of age, laboratory analysis, and in-hospital complications. Previous diabetes, blood pressure, respiratory rate, heart rate, \( \text{SpO}_2/\text{FiO}_2 \) ratio, neutrophils-to-lymphocytes ratio, and blood urea nitrogen at admission as associated with severe COVID-19. Preexisting comorbidities as diabetes and chronic hypertension have been shown to be associated with an increased risk for COVID-19 adverse outcomes in pregnant women (23, 24).

Most pregnant women were young and healthy before the admission due to COVID-19, which partially explains why abnormal vital signals and inflammatory markers are associated with the in-hospital severe/critical progression, instead of pre-existent comorbidities. Neutrophil-to-lymphocyte ratio and C-reactive protein were higher in the severe and critical COVID-19 group when compared to mild one. In fact, this ratio has been observed to be the most consistent abnormal hemocytometric finding in COVID-19 patients (25). In the multivariate modeling of ABC₂-SPH score (12), C-reactive protein is the inflammatory marker which was significant in the final model. We hypothesize that inflammatory markers could be covariables even more relevant for pregnant women, scoring proportionally higher than for general patients. Besides, physiological adaptations to the pregnancy affect the organ system in the maternal body, modifying, as well the response to infections.

The existing evidence is conflicting on whether pregnancy is an immunological contributor to severe progression of COVID-19 (26). A successful pregnancy depends on a responsive immune system, which explains reports of universal COVID-19 testing during pregnancy, that the vast majority is asymptomatic or has mild COVID-19 (26, 27). The unit maternal and feto–placental immune system is responsive, protecting both the mother and the fetus against treats from the environment (28). The placenta is a selective barrier, able to protect the developing fetus against infections, including SARS-CoV-2 virus infection (29). It also acts as an immunity-modulating organ, regulating immune responses of cells present both at the implantation site and systemically (30). However, evidence of fetal vascular malperfusion or thrombosis has been observed in COVID-19, which may be related to an exacerbated maternal systemic inflammatory response and hypercoagulable state (31, 32).

Notwithstanding, cardiopulmonary adaptive changes during pregnancy may increase the risk of hypoxemia and contribute to the increased severity of viral infections (33). The circulatory system is significantly adjusted during pregnancy, starting early in its course, driven by peripheral vasodilatation, increased heart rate and stroke volume, reduced pulmonary vascular resistance, and reduced pulmonary residual capacity. These changes may affect the course of viral infections (9, 33). For these reasons, although we believe that vital signals at admission might contribute to scoring in predictive models of COVID-19 outcomes during
pregnancy, the expected cut offs are affected by physiological changes during pregnancy and might not coincide with non-pregnant women. Besides, with hemodilution and rising glomerular filtration rate, there are modifications in the reference values for hemoglobin levels, proteins, creatinine, and urea (9), interfering in the performance of scores based on laboratory values. Therefore, it is comprehensible that scores used to predict mortality in general adults have limitations when used among pregnant women (34).

Another aspect of COVID-19 disease in pregnant women grounds on the overactivated renin–angiotensin system. This system plays a relevant role in maternal hemodynamic adaptations and in placentation and hypertensive disturbs during pregnancy (35). SARS-CoV-2 uses the protein angiotensin-converting enzyme the receptors 2 (ACE2) to invade cells, with potential implications for increased susceptibility to the virus during pregnancy (36). Obstetric outcomes were not the target in the current approach, even though they could be affected by COVID-19 (3, 5, 37).

Yet, this analysis has expected limitations that may affect the interpretation. Our sample size of pregnant women is limited. Maternal mortality was lower than Brazilian national rates (20), and the frequency of chronic hypertension was low. A specific predictive model for COVID-19 prognosis for inpatient pregnant women was not proposed. The results also do not apply to antenatal care since the inclusion criteria was pregnant women admitted with COVID-19. As a retrospective analysis, the quality of data as incompleteness might have occurred. Thus, we reduced the risk of inaccuracies by performing several quality checks and rechecking hospital medical records whenever necessary.

Based on our results, we warn against the use of non-pregnant COVID-19 prognosis scores in pregnant women to predict adverse outcomes without proper validation. While insufficient control of pandemic keeps worldwide, fast and efficient assessment of prognosis of the COVID-19 is of utmost importance for early identification of cases at higher risk of worse outcome in this highly vulnerable group of women. Although several studies developed and validated risk scores to estimate prognosis in COVID-19 patients, there is a lack of scores focused on pregnant women specificities. Studies using data pools across national systems or healthcare data sharing frameworks are necessary to rapidly join and use clinical information relevant to COVID-19 during the pregnancy. Martinez-Portilla et al. reported a national model to predict death among women of reproductive age with COVID-19, highlighting pregnancy as a risk factor for death, pneumonia and intensive care unit admission (38); however without proposing a prediction model. Villar et al. provided consistent evidence that COVID-19 substantially increases maternal morbidity and mortality, and neonatal complications, in a multinational prospective cohort study, without proposing a risk score (5). Evidence-based modelling could provide a proper prognosis score assessment tool that will help guide decision-making, develop patient care plans, and better allocate resources. Additionally, we believe that a team of intensive care with the support of obstetrics specialists is necessary to make better decisions around COVID-19 upon pregnancy, identifying and prioritizing the care of those who have a higher risk of morbidity and mortality.

Conclusions
In conclusion, this study has shown that the model ABC$_2$-SPH developed in Brazilian general patients was not able to identify adverse clinical outcomes in pregnant women with COVID-19. Prognosis markers of the COVID-19 clinical evolution upon pregnancy are not the same as the in-hospital population admitted with the disease. We warn against the use of general inpatients COVID-19 prognosis in pregnant women. A more useful model for clinical prognosis is necessary concerning the specificities of pregnancy affected by COVID-19.

**Abbreviations**

ACE2  
Angiotensin-Converting Enzyme the Receptors 2  
ARDS  
Acute respiratory distress syndrome  
AUROC  
Receiver Operating Characteristic Curve  
BMI  
body mass index  
COPD  
Chronic Obstructive Pulmonary Disease  
COVID-19  
Coronavirus Disease 2019  
FiO2  
Fraction Of Inspired Oxygen  
GAM  
Generalized Additive Models  
HCO3-  
bicarbonate  
IQR  
Interquartile Ranges  
LASSO  
Least Absolute Shrinkage and Selection Operator  
MAP  
Mean Arterial Pressure  
NL ratio  
neutrophils-to-lymphocytes ratio  
pCO2  
carbon dioxide partial pressure  
pH  
hydrogen potential  
pO2  
oxygen partial pressure
Declarations

Ethics approval and consent to participate

The study protocol was approved by the Brazilian National Commission for Research Ethics (CAAE 30350820.5.1001.0008). Individual informed consent was waived due to the severity of the situation and the use of unidentified data, based on medical chart review only. Additionally, administrative permissions to access and use the medical records were obtained from each institution.

Consent for publication

Not applicable.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was supported in part by Minas Gerais State Agency for Research and Development (Fundação de Amparo à Pesquisa do Estado de Minas Gerais - FAPEMIG) [grant number APQ-00208-20], National Institute of Science and Technology for Health Technology Assessment (Instituto de Avaliação de Tecnologias em Saúde – IATS)/ National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Científico e Tecnológico – CNPQ).
Nacional de Desenvolvimento Científico e Tecnológico - CNPq) [grant number 465518/2014-1], and CAPES Foundation (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) [grant number 88887.507149/2020-00].

Authors' contributions

MSM, MCP, ZSNR had substantial contributions to the conception or design of the work. ZSNR, RALPA, TLSS, AOM, ALBAS, BLF, CMR, CCRC, CSC, CR, DP, EC, EMSK, ERFM, FFMGA, FA, GPC, GANB, JCA, JMR, KBR, LBZ, LSP, LYBC, LEAS, MAF, MFLM, MHGJ, PJLM, RSCA, RCM, RP, RLSM, MCP, MSM had substantial contributions to the acquisition, analysis, or interpretation of data for the work. All authors read and approved the final manuscript.

Acknowledgments

We would like to thank the hospitals which are part of this collaboration, for supporting this project: Hospital São João de Deus, Hospital Regional Antônio Dias, Hospital Risoleta Tolentino Neves, Hospital Moinhos de Vento, Hospital Júlia Kubitschek, Hospital Mãe de Deus, Hospital Bruno Born, Hospital Santa Rosália, Hospital João XXIII, Hospital das Clínicas da Faculdade de Medicina de Botucatu, Hospital Universitário de Canoas, Hospital SOS Cârdio, Hospital Nossa Senhora da Conceição, Hospital Márcio Cunha, Hospital Tacchini, Hospital das Clínicas da Universidade Federal de Pernambuco.

We also thank all the clinical staff at those hospitals, who cared for the patients, and all undergraduate students who helped with data collection.

References

1. Carta MG, Scano A, Lindert J, Bonanno S, Rinaldi L, Fais S, et al. Association between the spread of COVID-19 and weather-climatic parameters. Eur Rev Med Pharmacol Sci. 2020;24(15):8226-31. Epub 2020/08/09.
2. Breitling LP. Global epidemiology and socio-economic development correlates of the reproductive ratio of COVID-19. Int Health. 2021. Epub 2021/03/09.
3. Ribeiro KB, Ribeiro AF, de Sousa Mascena Veras MA, de Castro MC. Social inequalities and COVID-19 mortality in the city of São Paulo, Brazil. Int J Epidemiol. 2021.
4. Souza; ASR, Amorim MMR. Mortalidade materna pela COVID-19 no Brasil. Rev Bras Saúde Mater Infant. 2021;21(Suppl 1):S257-S61.
5. Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, et al. Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study. JAMA Pediatr. 2021.
6. Nakamura-Pereira M, Amorim MMR, Pacagnella RdC, Takemoto MLS, Penso FCC, Rezende-Filho Jd, et al. COVID-19 and Maternal Death in Brazil: An Invisible Tragedy. Rev Bras Ginecol Obstet. 2020;42:445-7.
7. Rasmussen SA, Smulian JC, Lednicky JA, Wen TS, Jamieson DJ. Coronavirus Disease 2019 (COVID-19) and pregnancy: what obstetricians need to know. Am J Obstet Gynecol. 2020;222(5):415-26.
8. Savasi VM, Parisi F, Patanè L, Ferrazzi E, Frigerio L, Pellegrino A, et al. Clinical Findings and Disease Severity in Hospitalized Pregnant Women With Coronavirus Disease 2019 (COVID-19). Obstet Gynecol. 2020;136(2):252-8.

9. Soma-Pillay P, Nelson-Piercy C, Tolppanen H, Mebazaa A. Physiological changes in pregnancy. Cardiovasc J Afr. 2016;27(2):89-94.

10. Wastnedge EAN, Reynolds RM, van Boeckel SR, Stock SJ, Denison FC, Maybin JA, et al. Pregnancy and COVID-19. Physiol Rev. 2021;101(1):303-18.

11. Marcolino MS, Ziegelmann PK, Souza-Silva MVR, do Nascimento IJB, Oliveira LM, Monteiro LS, et al. Clinical characteristics and outcomes of patients hospitalized with COVID-19 in Brazil: results from the Brazilian COVID-19 Registry. Int J Infect Dis. 2021;11(21):00030-8.

12. Marcolino MS, Pires MC, Ramos LEF, Silva RT, Oliveira LM, Carvalho RLR, et al. ABC2-SPH risk score for in-hospital mortality in COVID-19 patients: development, external validation and comparison with other available scores. Int J Infect Dis. 2021;110:281-308. Epub 2021/07/27.

13. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806-8. Epub 2007/10/07.

14. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-81.

15. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95(103208):9.

16. Organization WH. Clinical management of COVID-19: interim guidance, 27 May 2020. Geneva: World Health Organization, 2020 2020. Report No.: Contract No.: WHO/2019-nCoV/clinical/2020.5.

17. Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1-73. Epub 2015/01/07.

18. Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies. Ann Intern Med. 2019;170(1):51-8. Epub 2019/01/01.

19. Organization WH. WHO Coronavirus (COVID-19) Dashboard. 2021; Available from: https://covid19.who.int/region/amro/country/br. Accessed 16 August 2021.

20. Rodrigues A, Lacerda L, Francisco RPV. Brazilian Obstetric Observatory. 2021. Available from: https://observatorioobstetrico.shinyapps.io/covid_gesta_puerp_br/. Accessed 16 August 2021.

21. Ebell MH, Cai X, Lennon R, Tarn DM, Mainous AG, 3rd, Zgierska AE, et al. Development and Validation of the COVID-NoLab and COVID-SimpleLab Risk Scores for Prognosis in 6 US Health Systems. J Am Board Fam Med. 2021;34(Suppl):S127-S35. Epub 2021/02/25.

22. Altschul DJ, Unda SR, Benton J, de la Garza Ramos R, Cezayirli P, Mehler M, et al. A novel severity score to predict inpatient mortality in COVID-19 patients. Sci Rep. 2020;10(1):16726. Epub 2020/10/09.
23. Metz TD, Clifton RG, Hughes BL, Sandoval G, Saade GR, Grobman WA, et al. Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19). Obstet Gynecol. 2021;137(4):571-80. Epub 2021/02/10.
24. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. Epub 2020/09/03.
25. Khartabil TA, Russcher H, van der Ven A, de Rijke YB. A summary of the diagnostic and prognostic value of hemocytometry markers in COVID-19 patients. Crit Rev Clin Lab Sci. 2020;57(6):415-31. Epub 2020/06/23.
26. Hanna N, Hanna M, Sharma S. Is pregnancy an immunological contributor to severe or controlled COVID-19 disease? Am J Reprod Immunol. 2020;84(5):e13317. Epub 2020/08/07.
27. Crovetto F, Crispi F, Llurba E, Pascal R, Larroya M, Trilla C, et al. Impact of SARS-CoV-2 Infection on Pregnancy Outcomes: A Population-Based Study. Clin Infect Dis. 2021;8(10).
28. Mor G, Aldo P, Alvero AB. The unique immunological and microbial aspects of pregnancy. Nat Rev Immunol. 2017;17(8):469-82.
29. Komine-Aizawa S, Takada K, Hayakawa S. Placental barrier against COVID-19. Placenta. 2020;99:45-9.
30. Vianna FSL, Fraga LR, Abeche AM, Silva AAD, Sanseverino MTV, Schuler-Faccini L. COVID-19 during pregnancy and adverse outcomes: Concerns and recommendations from The Brazilian Teratology Information Service. Genet Mol Biol. 2021;44.
31. Shanes ED, Mithal LB, Otero S, Azad HA, Miller ES, Goldstein JA. Placental Pathology in COVID-19. Am J Clin Pathol. 2020;154(1):23-32.
32. Baergen RN, Heller DS. Placental Pathology in Covid-19 Positive Mothers: Preliminary Findings. Pediatr Dev Pathol. 2020;23(3):177-80.
33. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. N Engl J Med. 2014;370(23):2211-8. Epub 2014/06/05.
34. Bandeira AR, Rezende CA, Reis ZS, Barbosa AR, Peret FJ, Cabral AC. Epidemiologic profile, survival, and maternal prognosis factors among women at an obstetric intensive care unit. Int J Gynaecol Obstet. 2014;124(1):63-6. Epub 2013/10/22.
35. Merrill DC, Karoly M, Chen K, Ferrario CM, Brosnihan KB. Angiotensin-(1–7) in normal and preeclamptic pregnancy. Endocrine. 2002;18(3):239-45.
36. Cruz NAN, Stoll D, Casarini DE, Bertagnolli M. Role of ACE2 in pregnancy and potential implications for COVID-19 susceptibility. Clin Sci (Lond). 2021;135(15):1805-24. Epub 2021/08/03.
37. Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2020;2(2):25.
38. Martinez-Portilla RJ, Sotiriadis A, Chatzakis C, Torres-Torres J, Espino YSS, Sandoval-Mandujano K, et al. Pregnant women with SARS-CoV-2 infection are at higher risk of death and pneumonia: propensity score matched analysis of a nationwide prospective cohort (COV19Mx). Ultrasound Obstet Gynecol. 2021;57(2):224-31. Epub 2020/12/16.
Figure 1

Flowchart of COVID-19 pregnant women included in the study
Figure 2

Discrimination of $\text{ABC}_2$-SPH Score in the sample of pregnant women ($n=85$) to predict death (A), death or mechanical ventilation (B) or critical disease (C)

Figure 3

The observed and expected death (A), composite of mechanical ventilation or death (B) and severe/critical COVID-19 (C), for each quartile of pregnant women risk

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SUPPLEMENTARYMATERIAL.docx